Federal Agricultural Mortgage A's 15min chart indicates RSI overbought and KDJ death cross.

Federal Agricultural Mortgage A's 15-minute chart has exhibited signs of overbought conditions, as indicated by the RSI and KDJ metrics. Specifically, the KDJ Death Cross at 09/17/2025 11:45 suggests a rapid increase in stock price that exceeds fundamental support levels, indicating a potential shift in momentum towards the downside. This may lead to a further decrease in stock price.

X4 Pharmaceuticals (NASDAQ: XFOR) has announced a significant strategic restructuring aimed at streamlining operations and focusing on its 4WARD Phase 3 trial in chronic neutropenia patients. The restructuring includes a 50% workforce reduction, expected to generate $13 million in annual cost savings. Key management changes include John Volpone's appointment as COO while retaining his President role, and Dr. Adam Craig (Executive Chairman) taking oversight of clinical development. Several executives, including the Chief Legal Officer, former COO, Chief Commercial Officer, and Chief Medical Officer, will be departing the company.

The company has also announced significant financial milestones. On August 12, 2025, X4 Pharmaceuticals successfully closed an upsized $85 million private placement, exceeding the initially announced $60 million offering. The financing includes 11,040,776 shares of common stock and pre-funded warrants to purchase 48,852,772 shares. The offering was led by Coastlands Capital with participation from notable investors including Empery Asset Management, Bain Capital Life Sciences, and NEA. The proceeds will support the continued development of mavorixafor for potential approval in chronic neutropenia and its commercialization in WHIM syndrome.

In addition, X4 Pharmaceuticals has announced inducement grants to three new executive officers under its 2019 Inducement Plan. The grants include stock options for 12.7 million shares issued on August 12, 2025, and an additional 1.4 million shares on August 14, 2025. The initial grants were distributed among Dr. Adam Craig, John Volpone (4.25 million shares each), and David Kirske (2.83 million shares) at $1.42 per share. Additional grants were issued at $3.14 per share following X4's $85 million private placement. The options feature varying vesting schedules over 18-36 months, subject to performance conditions and continued employment.

X4 Pharmaceuticals has also reported positive Phase 2 trial data for mavorixafor in treating chronic neutropenia at the 30th EHA Congress. The 6-month study involving 23 participants demonstrated that oral, once-daily mavorixafor effectively increased absolute neutrophil count (ANC) both as monotherapy and in combination with G-CSF. Key findings showed that patients with severe chronic neutropenia achieved nearly 3-fold increases in mean ANC levels, and 89% of participants were able to reduce or discontinue injectable G-CSF while maintaining normal ANC levels. The drug was well-tolerated with no drug-related serious adverse events. A sub-study revealed that treated patients' functional neutrophil levels were comparable to healthy donors.

The company is currently conducting a global Phase 3 pivotal trial, expected to complete enrollment in Q3/Q4 2025. X4 Pharmaceuticals believes oral mavorixafor could offer better disease control with reduced treatment burden for CN patients.